ClinicalTrials.gg
CompletedNCT00327015Updated Apr 29, 2015Results posted

A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

A Phase 3 interventional study of Saxagliptin and Saxagliptin in Diabetes, sponsored by AstraZeneca. Completed at 211 sites in 13 countries. Open to participants aged 18 Years to 77 Years. Per ClinicalTrials.gov, last updated 2015-04-29.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,306
Allocation
Randomized
Ages
18 Years to 77 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies testing saxagliptin in Diabetes Mellitus — none open to participants now, none under way, none of them phase 3. saxagliptin · Diabetes Mellitus.

Enrollment
Largest of 10
1,306 · median 66
Started
2006
with 2 others
Phase 3
4 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
7 of 10
AstraZeneca

Among the 10 studies testing saxagliptin in Diabetes Mellitus, this one has the largest enrollment, is one of 3 that started in 2006, is one of 4 in phase 3, and was the 3rd registered.

Diabetes Mellitus

8,294 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

None of the 10 studies testing saxagliptin in Diabetes Mellitus is open now. The open studies under Diabetes Mellitus, anywhere →

About saxagliptin

saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 77 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing saxagliptin in Diabetes Mellitus as a file.
02

Study summary

The purpose of this trial is to understand if adding saxagliptin to metformin therapy is safe and works better than taking either saxagliptin or metformin alone

Read the detailed description

All subjects will participate in a lead-in period, and qualifying subjects will continue into a short-term randomized treatment period. Subjects who complete the short-term period will be eligible to enter the long term extension period. Also, subjects in the short-term period who have an elevated blood sugar that requires additional medication for blood sugar control will be eligible to enter the long-term treatment extension period where they will receive pioglitazone (rescue medication) added onto their blinded study medication

03

Conditions studied

  • Diabetes

Browse trials for

04

Who can participate

Ages eligible
18 Years to 77 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes
  • Inadequate blood sugar control
  • No current treatment with other medications to lower blood sugar

Exclusion criteria

Exclusion Criteria:

  • Major heart, liver or kidney problems
  • Pregnant or breast feeding
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,306 participants (actual)

Study arms

  • Experimental
    Saxagliptin and Metformin (A)

    PLUS open-label pioglitazone (as needed as rescue medication)

    Drug: Saxagliptin · Drug: Metformin · Drug: pioglitazone

  • Experimental
    Saxagliptin and Metformin (B)

    PLUS open-label pioglitazone (as needed as rescue medication)

    Drug: Saxagliptin · Drug: Metformin · Drug: pioglitazone

  • Experimental
    Saxagliptin and Placebo (C)

    PLUS open-label pioglitazone (as needed as rescue medication)

    Drug: Saxagliptin · Drug: Placebo · Drug: pioglitazone

  • Active comparator
    Metformin and Placebo (D)

    PLUS open-label pioglitazone (as needed as rescue medication)

    Drug: Metformin · Drug: Placebo · Drug: pioglitazone

Interventions

  • Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)

    Also known as: BMS-477118

  • Coated tablets, PO, 5 mg, Daily (6 months ST, 12 months LT)

    Also known as: BMS-477118

  • Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)

  • DrugPlacebo

    Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)

  • Tablets, Oral, 15-45 mg, as needed (12 months LT)

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (A1C) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy

    Mean change from baseline in A1C at Week 24, adjusted for baseline value.

    Time frame: Baseline, Week 24

  2. Change From Baseline in A1C at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy

    Mean change from baseline in A1C at Week 24, adjusted for baseline value.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy

    Mean change from baseline in FPG at Week 24, adjusted for baseline value.

    Time frame: Baseline, Week 24

  2. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy

    Mean change from baseline in FPG at Week 24, adjusted for baseline value.

    Time frame: Baseline, Week 24

  3. Percentage of Participants Achieving A1C < 7% at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy

    Percentage of participants achieving A1C \< 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus metformin versus saxagliptin alone at Week 24.

    Time frame: Week 24

  4. Percentage of Participants Achieving A1C < 7% at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy

    Percentage of participants achieving A1C \< 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus metformin versus metformin alone at Week 24.

    Time frame: Week 24

  5. Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy

    Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline value.

    Time frame: Baseline, Week 24

  6. Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy

    Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjsuted for baseline value.

    Time frame: Baseline, Week 24

  7. Percentage of Participants Achieving A1C ≤6.5% at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy

    Percentage of participants achieving A1C ≤6.5%, at each dose of saxagliptin plus metformin versus saxagliptin alone at Week 24.

    Time frame: Week 24

  8. Percentage of Participants Achieving A1C ≤6.5% at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy

    Percentage of participants achieving A1C ≤6.5%, at each dose of saxagliptin plus metformin versus metformin alone at Week 24.

    Time frame: Week 24

  9. Percentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy

    Percentage of participants requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24-week treatment period at each dose of saxagliptin plus metformin versus saxagliptin alone.

    Time frame: Week 24

  10. Percentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy

    Percentage of participants requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24-week treatment period at each dose of saxagliptin plus metformin versus metformin alone.

    Time frame: Week 24

07

Results

Posted Sep 25, 2009

Participant flow

Participant flow — Overall Study
MilestoneSaxagliptin 5 mg + MetforminSaxagliptin 10 mg + MetforminSaxagliptin 10 mgMetformin
Started320323335328
Completed study without being rescued179177113144
Completed229231209219
Not completed9192126109
Withdrew: Lack of efficacy18183529
Withdrew: Withdrawal of consent by subject20242825
Withdrew: Lost to follow-up22232922
Withdrew: Adverse event14101414
Withdrew: Subject no longer meets study criteria4287
Withdrew: Poor/noncompliance11845
Withdrew: Physician decision0132
Withdrew: Death1223
Withdrew: Pregnancy0211
Withdrew: Administrative reason by sponsor1221

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (A1C) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy

Mean change from baseline in A1C at Week 24, adjusted for baseline value.

Time frame:
Baseline, Week 24
Reported as:
Mean · percent
Change From Baseline in Hemoglobin A1c (A1C) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy
percentSaxagliptin 5 mg + MetforminSaxagliptin 10 mg + MetforminSaxagliptin 10 mg
Baseline Mean9.41 ± 0.0729.53 ± 0.0699.61 ± 0.075
Week 24 Mean6.93 ± 0.0667.02 ± 0.0677.86 ± 0.085
Adjusted Mean Change from Baseline-2.53 ± 0.070-2.49 ± 0.069-1.69 ± 0.069
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy

Mean change from baseline in FPG at Week 24, adjusted for baseline value.

Time frame:
Baseline, Week 24
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy
mg/dLSaxagliptin 5 mg + MetforminSaxagliptin 10 mg + MetforminSaxagliptin 10 mg
Baseline Mean198.9 ± 3.17204.3 ± 3.35200.9 ± 3.03
Week 24 Mean140.2 ± 2.39140.1 ± 2.34169.9 ± 3.20
Adjusted Mean Change from Baseline-59.8 ± 2.34-62.2 ± 2.34-30.9 ± 2.30
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy

Mean change from baseline in FPG at Week 24, adjusted for baseline value.

Time frame:
Baseline, Week 24
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy
mg/dLSaxagliptin 5 mg + MetforminSaxagliptin 10 mg + MetforminMetformin
Baseline Mean198.9 ± 3.17204.3 ± 3.35199.1 ± 3.28
Week 24 Mean140.2 ± 2.39140.1 ± 2.34152.7 ± 2.80
Adjusted Mean Change from Baseline-59.8 ± 2.34-62.2 ± 2.34-47.3 ± 2.33
SecondaryPercentage of Participants Achieving A1C < 7% at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy

Percentage of participants achieving A1C \< 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus metformin versus saxagliptin alone at Week 24.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving A1C < 7% at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy
Percentage of participantsSaxagliptin 5 mg + MetforminSaxagliptin 10 mg + MetforminSaxagliptin 10 mg
Percentage of Participants Achieving A1C < 7% at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy60.359.732.2
SecondaryPercentage of Participants Achieving A1C < 7% at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy

Percentage of participants achieving A1C \< 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus metformin versus metformin alone at Week 24.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving A1C < 7% at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy
Percentage of participantsSaxagliptin 5 mg + MetforminSaxagliptin 10 mg + MetforminMetformin
Percentage of Participants Achieving A1C < 7% at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy60.359.741.1
SecondaryChanges From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy

Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline value.

Time frame:
Baseline, Week 24
Reported as:
Mean · mg*min/dL
Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy
mg*min/dLSaxagliptin 5 mg + MetforminSaxagliptin 10 mg + MetforminSaxagliptin 10 mg
Baseline Mean55531 ± 1116.557219 ± 1169.657584 ± 1143.4
Week 24 Mean35324 ± 890.035790 ± 888.941229 ± 1050.9
Adjusted Mean Change from Baseline-21080 ± 836.5-21336 ± 869.6-16054 ± 826.7
PrimaryChange From Baseline in A1C at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy

Mean change from baseline in A1C at Week 24, adjusted for baseline value.

Time frame:
Baseline, Week 24
Reported as:
Mean · percent
Change From Baseline in A1C at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy
percentSaxagliptin 5 mg + MetforminSaxagliptin 10 mg + MetforminMetformin
Baseline Mean9.41 ± 0.0729.53 ± 0.0699.43 ± 0.073
Week 24 Mean6.93 ± 0.0667.02 ± 0.0677.48 ± 0.084
Adjusted Mean Change from Baseline-2.53 ± 0.070-2.49 ± 0.069-1.99 ± 0.069
SecondaryChanges From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy

Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjsuted for baseline value.

Time frame:
Baseline, Week 24
Reported as:
Mean · mg*min/dL
Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy
mg*min/dLSaxagliptin 5 mg + MetforminSaxagliptin 10 mg + MetforminMetformin
Baseline Mean55531 ± 1116.557219 ± 1169.657937 ± 1281.7
Week 24 Mean35324 ± 890.035790 ± 888.942428 ± 1082.1
Adjusted Mean Change from Baseline-21080 ± 836.5-21336 ± 869.6-15005 ± 857.0
SecondaryPercentage of Participants Achieving A1C ≤6.5% at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy

Percentage of participants achieving A1C ≤6.5%, at each dose of saxagliptin plus metformin versus saxagliptin alone at Week 24.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving A1C ≤6.5% at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy
Percentage of ParticipantsSaxagliptin 5 mg + MetforminSaxagliptin 10 mg + MetforminSaxagliptin 10 mg
Percentage of Participants Achieving A1C ≤6.5% at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy45.340.620.3
SecondaryPercentage of Participants Achieving A1C ≤6.5% at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy

Percentage of participants achieving A1C ≤6.5%, at each dose of saxagliptin plus metformin versus metformin alone at Week 24.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving A1C ≤6.5% at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy
Percentage of participantsSaxagliptin 5 mg + MetforminSaxagliptin 10 mg + MetforminMetformin
Percentage of Participants Achieving A1C ≤6.5% at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy45.340.629.0
SecondaryPercentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy

Percentage of participants requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24-week treatment period at each dose of saxagliptin plus metformin versus saxagliptin alone.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy
Percentage of participantsSaxagliptin 5 mg + MetforminSaxagliptin 10 mg + MetforminSaxagliptin 10 mg
Percentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy7.55.921.2
SecondaryPercentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy

Percentage of participants requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24-week treatment period at each dose of saxagliptin plus metformin versus metformin alone.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy
Percentage of participantsSaxagliptin 5 mg + MetforminSaxagliptin 10 mg + MetforminMetformin
Percentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy7.55.910.1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Metformin—15/328 (4.6%)106/328 (32.3%)
Saxagliptin 10 mg—16/335 (4.8%)106/335 (31.6%)
Saxagliptin 10 mg + Metformin—22/323 (6.8%)122/323 (37.8%)
Saxagliptin 5 mg + Metformin—16/320 (5%)116/320 (36.3%)
Most frequent serious events
Showing 10 of 70
Most frequent serious events
EventMetforminSaxagliptin 10 mgSaxagliptin 10 mg + MetforminSaxagliptin 5 mg + Metformin
MYOCARDIAL INFARCTIONCardiac disorders0/3280/3352/3230/320
CARDIAC FAILURECardiac disorders2/3280/3350/3230/320
ATRIAL FIBRILLATIONCardiac disorders2/3280/3351/3231/320
ACUTE MYOCARDIAL INFARCTIONCardiac disorders2/3280/3350/3231/320
CORONARY ARTERY DISEASECardiac disorders0/3280/3350/3231/320
CHOLECYSTITISHepatobiliary disorders0/3280/3350/3231/320
CEREBRAL INFARCTIONNervous system disorders0/3280/3350/3231/320
FACIAL NERVE DISORDERNervous system disorders0/3280/3350/3231/320
GASTRITISGastrointestinal disorders0/3280/3351/3231/320
HIATUS HERNIAGastrointestinal disorders0/3280/3350/3231/320
Most frequent other events
Most frequent other events
EventMetforminSaxagliptin 10 mgSaxagliptin 10 mg + MetforminSaxagliptin 5 mg + Metformin
DIARRHOEAGastrointestinal disorders30/32812/33541/32326/320
HEADACHENervous system disorders18/32831/33536/32331/320
NASOPHARYNGITISInfections and infestations19/32824/33519/32329/320
HYPERTENSIONVascular disorders17/32819/33521/32327/320
URINARY TRACT INFECTIONInfections and infestations25/32823/33522/32313/320
INFLUENZAInfections and infestations19/32817/33513/32320/320
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations10/32814/33519/32315/320

Baseline characteristics

Age, Continuous
Age, Continuous(years)Saxagliptin 5 mg + MetforminSaxagliptin 10 mg + MetforminSaxagliptin 10 mgMetforminTotal
Mean51.95 ± 10.4352.08 ± 11.5952.09 ± 10.1751.83 ± 10.7451.99 ± 10.73
Sex: Female, Male
Sex: Female, Male(Participants)Saxagliptin 5 mg + MetforminSaxagliptin 10 mg + MetforminSaxagliptin 10 mgMetforminTotal
Female155177166165663
Male165146169163643
08

Study locations

211 sites
  • East Bay Clinical Trial Center
    Concord, California 94520, United States
  • Encompass Clinical Research
    Encinitas, California 92024, United States
  • Community Clinical Trials
    Orange, California 92868, United States
  • Coastal Biomedical Research Inc
    Santa Monica, California 90404, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • St. Joseph'S Medical Associates
    Stockton, California 95204, United States
  • Clinical Therapeutics Corporation
    Coral Gables, Florida 33134, United States
  • Florida Research Network, Llc
    Gainesville, Florida 32605, United States
  • Fpa Clinical Research
    Kissimmee, Florida 34741, United States
  • Emerald Coast Research Group
    Marianna, Florida 32446, United States
  • Baptist Diabetes Associates
    Miami, Florida 33156, United States
  • Middle Georgia Drug Study Center, Llc
    Perry, Georgia 31069, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
  • Adviso Medical Research, Llc
    Chicago, Illinois 60617, United States
  • Deerbrook Medical Associates
    Vernon Hills, Illinois 60061, United States
  • Physicians Research Group
    Indianapolis, Indiana 46250, United States
  • Professional Network Research Of Kansas
    Wichita, Kansas 67203, United States
  • Medical Arts Research Collaborative, Llc
    Excelsior Springs, Missouri 64024, United States
  • Nevada Alliance Against Diabetes
    N. Las Vegas, Nevada 89030, United States
  • Metrolina Medical Research
    Charlotte, North Carolina 28209, United States
  • Durham Internal Medicine Assoc.
    Durham, North Carolina 27704, United States
  • Down East Medical Associates
    Morehead City, North Carolina 28557, United States
  • Midwest Regional Research, Inc.
    Bellbrook, Ohio 45305, United States
  • Massillon Family Practice
    Massillon, Ohio 44646, United States
  • Your Diabetes Endocrine Nutrition Group
    Mentor, Ohio 44060, United States
  • Newark Physician Associates
    Newark, Ohio 43055, United States
  • Preferred Primary Care Physicians
    Uniontown, Pennsylvania 15401, United States
  • Safe Harbor Clinical Research
    E. Providence, Rhode Island 02914, United States
  • Internal Medicine Of Greer
    Greer, South Carolina 29651, United States
  • Middle Tennessee Clinical Research
    Fayetteville, Tennessee 37334, United States
  • Frontier Clinical Research, Llc.
    Memphis, Tennessee 38103, United States
  • Capital Medical Clinic, Llp
    Austin, Texas 78705, United States
  • Endocrine Associates
    Houston, Texas 77004, United States
  • Advances In Health,Inc
    Houston, Texas 77030, United States
  • Juno Research, Llc
    Houston, Texas 77036, United States
  • Non Invasive Cardiovascular Pa
    Houston, Texas 77074, United States
  • Tiena Health Research
    Irving, Texas 75039, United States
  • Diabetes Center Of The Southwest
    Midland, Texas 79705, United States
  • Hill Country Medical Associates
    New Braunfels, Texas 78130, United States
  • Pearland Primary Care Associates, Llp
    Pearland, Texas 77584, United States
  • Med-Cure Primary Care Physicians
    Rosenberg, Texas 77471, United States
  • Gsa Research
    San Antonio, Texas 78213, United States
  • Covenant Clinical Research, Pa
    San Antonio, Texas 78229, United States
  • S.A.M. Clinical Research Center
    San Antonio, Texas 78229, United States
  • Seven Corners Medical Research Center
    Falls Church, Virginia 22044, United States
  • Salem Va Medical Ctr Research & Devlopment
    Salem, Virginia 24153, United States
  • Physicians Clinic Of Spokane
    Spokane, Washington 99204, United States
  • Local Institution
    Belgrano, Buenos Aires C1426EGP, Argentina
  • Local Institution
    Capital Federal, Buenos Aires 1221, Argentina
  • Local Institution
    Capital Federal, Buenos Aires C1406GWY, Argentina
  • Local Institution
    Chacabuco, Buenos Aires 6740, Argentina
  • Local Institution
    La Plata, Buenos Aires B1902COS, Argentina
  • Local Institution
    Moron, Buenos Aires B1708IFF, Argentina
  • Local Institution
    San Martin, Buenos Aires CP1405, Argentina
  • Local Institution
    San Pedro, Buenos Aires B2930DGO, Argentina
  • Local Institution
    Zarate, Buenos Aires 2800, Argentina
  • Local Institution
    Rosario, Santa Fe CP2000, Argentina
  • Local Institution
    Lanus Este, Tucuman 1824, Argentina
  • Local Institution
    Buenos Aires, 1121, Argentina
  • Local Institution
    Buenos Aires, B7602CBM, Argentina
  • Local Institution
    Buenos Aires, C1117ABH, Argentina
  • Local Institution
    Buenos Aires, C1408INH, Argentina
  • Local Institution
    Buenos Aires, C1425AGC, Argentina
  • Local Institution
    Buenos Aires, C1505CWB, Argentina
  • Local Institution
    Mendoza, CP5500, Argentina
  • Local Institution
    Salta, 4406, Argentina
  • Local Institution
    Salta, A4400EMI, Argentina
  • Local Institution
    San Juan, 5400, Argentina
  • Local Institution
    Fortaleza, Ceara 60021, Brazil
  • Local Institution
    Fortaleza, Ceara 60430, Brazil
  • Local Institution
    Goiania, Goias 74110, Brazil
  • Local Institution
    Belem, Para 66073, Brazil
  • Local Institution
    Recife, Pe 52051, Brazil
  • Local Institution
    Porto Alegre, Rio Grande Do Sul 90035, Brazil
  • Local Institution
    Campinas, Sao Paulo 13059, Brazil
  • Local Institution
    Marília, Sao Paulo 17519, Brazil
  • Local Institution
    Sao Paulo, 01244, Brazil
  • Local Institution
    Sao Paulo, 04020, Brazil
  • Local Institution
    Aschaffenburg, 63739, Germany
  • Local Institution
    Bad, 37431, Germany
  • Local Institution
    Dresden, 01307, Germany
  • Local Institution
    Dresden, O1219, Germany
  • Local Institution
    Duisburg, 47051, Germany
  • Local Institution
    Heidelberg, 69120, Germany
  • Local Institution
    Kuenzing, 94550, Germany
  • Local Institution
    Ludwigshafen, 67073, Germany
  • Local Institution
    Magdeburg, 39112, Germany
  • Local Institution
    Mainz, 55116, Germany
  • Local Institution
    Mannheim, 68161, Germany
  • Local Institution
    Saarbrücken, 66119, Germany
  • Local Institution
    Vellmar, 34246, Germany
  • Local Institution
    Wangen Im Allgau, 88239, Germany
  • Local Institution
    Eger, 3300, Hungary
  • Local Institution
    Gyula, 5700, Hungary
  • Local Institution
    Szentes, 6600, Hungary
  • Local Institution
    Szigetvár, 7900, Hungary
  • Local Institution
    Érd, 2030, Hungary
  • Local Institution
    Panjagutta, Hyderabad, Andhra Pradesh 500082, India
  • Local Institution
    Vasanth Nagar, Bangalore 560052, India
  • Local Institution
    Bangalore, Karnataka 560010, India

Showing the first 100 of 211 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R; CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009 Jun;11(6):611-22. doi: 10.1111/j.1463-1326.2009.01056.x. PubMed 19515181 ↗
  • Gnesin F, Thuesen ACB, Kahler LKA, Madsbad S, Hemmingsen B. Metformin monotherapy for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2. PubMed 32501595 ↗
  • Cook W, Minervini G, Bryzinski B, Hirshberg B. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgrad Med. 2014 Oct;126(6):19-32. doi: 10.3810/pgm.2014.10.2818. PubMed 25414932 ↗
  • Karyekar CS, Frederich R, Ravichandran S. Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin. Int J Clin Pract. 2013 Aug;67(8):759-67. doi: 10.1111/ijcp.12212. Epub 2013 Jun 24. PubMed 23795975 ↗
  • Pfutzner A, Paz-Pacheco E, Allen E, Frederich R, Chen R; CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab. 2011 Jun;13(6):567-76. doi: 10.1111/j.1463-1326.2011.01385.x. PubMed 21342412 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Nov 2007 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2009, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2006
First posted
May 17, 2006
Start
May 2006
Primary completionActual
Nov 2007
CompletionActual
Dec 2008
Results first posted
Sep 25, 2009
Last update
Apr 29, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00327015
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 17, 2006
Start date
May 2006
Primary completion
Nov 2007
Completion
Dec 2008
Results posted
Sep 25, 2009
Last update
Apr 29, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Saxagliptin · Metformin

Start the discussion